Switch theme
Sign up to access all valuation multiples
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
2007
6
LTM Revenue $1.1M
Last FY EBITDA -$3.9M
$0.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prostatype Genomics has a last 12-month revenue (LTM) of $1.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prostatype Genomics achieved revenue of $21K and an EBITDA of -$3.9M.
Prostatype Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prostatype Genomics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | XXX | $21K | XXX | XXX | XXX |
| Gross Profit | $1.1M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 964% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$3.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -18791% | XXX | XXX | XXX |
| EBIT | -$46.3M | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | -4100% | XXX | -20530% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$4.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -20629% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Prostatype Genomics's stock price is SEK 1 (or $0).
Prostatype Genomics has current market cap of SEK 14.4M (or $1.5M), and EV of SEK 5.1M (or $0.5M).
See Prostatype Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.5M | $1.5M | XXX | XXX | XXX | XXX | $-0.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Prostatype Genomics has market cap of $1.5M and EV of $0.5M.
Prostatype Genomics's trades at 25.6x EV/Revenue multiple, and -0.1x EV/EBITDA.
Equity research analysts estimate Prostatype Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prostatype Genomics's P/E ratio is not available.
See valuation multiples for Prostatype Genomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5M | XXX | $1.5M | XXX | XXX | XXX |
| EV (current) | $0.5M | XXX | $0.5M | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 25.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProstatype Genomics's revenue per employee in the last FY averaged $3K, while opex per employee averaged $0.7M for the same period.
Prostatype Genomics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prostatype Genomics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prostatype Genomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -18791% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1111% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21493% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prostatype Genomics acquired XXX companies to date.
Last acquisition by Prostatype Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Prostatype Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prostatype Genomics founded? | Prostatype Genomics was founded in 2007. |
| Where is Prostatype Genomics headquartered? | Prostatype Genomics is headquartered in Sweden. |
| How many employees does Prostatype Genomics have? | As of today, Prostatype Genomics has 6 employees. |
| Is Prostatype Genomics publicy listed? | Yes, Prostatype Genomics is a public company listed on STO. |
| What is the stock symbol of Prostatype Genomics? | Prostatype Genomics trades under PROGEN ticker. |
| When did Prostatype Genomics go public? | Prostatype Genomics went public in 2020. |
| Who are competitors of Prostatype Genomics? | Similar companies to Prostatype Genomics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Prostatype Genomics? | Prostatype Genomics's current market cap is $1.5M |
| What is the current revenue of Prostatype Genomics? | Prostatype Genomics's last 12 months revenue is $1.1M. |
| What is the current EV/Revenue multiple of Prostatype Genomics? | Current revenue multiple of Prostatype Genomics is 5.1x. |
| Is Prostatype Genomics profitable? | Yes, Prostatype Genomics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
